請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66448完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林亮音 | |
| dc.contributor.author | Yu-Feng Lin | en |
| dc.contributor.author | 林毓棼 | zh_TW |
| dc.date.accessioned | 2021-06-17T00:36:20Z | - |
| dc.date.available | 2017-03-02 | |
| dc.date.copyright | 2012-03-02 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-02-02 | |
| dc.identifier.citation | 1.中華民國97年行政院衛生署國民健康局癌症登記報告；2010
2.McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood. 1983;62(1):1-13. 3.Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74(1):395-408. 4.Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993;329(13):909-914. 5.Bizzozero OJ, Jr., Johnson KG, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. N Engl J Med. 1966;274(20):1095-1101. 6.Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology. 2004;233(2):313-321. 7.Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115(1):23-35. 8.Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418-429. 9.Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451-458. 10.Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625. 11.Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951. 12.Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004;50(3):197-222. 13.Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494. 14.Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31 Pt 2:2349-2370. 15.de Greef GE, van Putten WL, Boogaerts M, et al. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol. 2005;128(2):184-191. 16.Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. 17.Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001;13(6):463-469. 18.Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91(12):4480-4488. 19.Guitart AV, Hammoud M, Dello Sbarba P, Ivanovic Z, Praloran V. Slow-cycling/quiescence balance of hematopoietic stem cells is related to physiological gradient of oxygen. Exp Hematol. 2010;38(10):847-851. 20.Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010;29(2):285-293. 21.Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928-5935. 22.Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 1991;51(22):6098-6102. 23.Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56(5):941-943. 24.Deeb G, Vaughan MM, McInnis I, et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res. 2011;35(5):579-584. 25.Kubota Y, Takubo K, Suda T. Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun. 2008;366(2):335-339. 26.Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007;26(2):333-339. 27.Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide. 2008;19(2):205-216. 28.Ahn JK, Koh EM, Cha HS, et al. Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford). 2008;47(6):834-839. 29.Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2003;5(4):R193-201. 30.Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther. 2009;8(5):1148-1156. 31.Kiang JG, Tsen KT. Biology of hypoxia. Chin J Physiol. 2006;49(5):223-233. 32.Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer. 2006;94(1):1-7. 33.Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553-560. 34.Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21(2):138-167. 35.Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993;194(2):720-725. 36.Nakayama M, Takahashi K, Kitamuro T, Murakami O, Shirato K, Shibahara S. Transcriptional control of adrenomedullin induction by phorbol ester in human monocytic leukemia cells. Eur J Biochem. 2000;267(12):3559-3566. 37.Kubo A, Minamino N, Isumi Y, Kangawa K, Dohi K, Matsuo H. Adrenomedullin production is correlated with differentiation in human leukemia cell lines and peripheral blood monocytes. FEBS Lett. 1998;426(2):233-237. 38.Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer. 2007;121(1):21-32. 39.Kohno M, Kano H, Horio T, Yokokawa K, Yasunari K, Takeda T. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension. 1995;25(6):1185-1190. 40.Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett. 1996;378(1):83-87. 41.Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology. 1998;139(8):3432-3441. 42.Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod. 2000;6(9):811-819. 43.Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest. 2008;118(1):40-50. 44.Iwase T, Nagaya N, Fujii T, et al. Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation. 2005;111(3):356-362. 45.Marinoni E, Di Iorio R, Letizia C, Villaccio B, Scucchi L, Cosmi EV. Immunoreactive adrenomedullin in human fetoplacental tissues. Am J Obstet Gynecol. 1998;179(3 Pt 1):784-787. 46.Allaker RP, Zihni C, Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol Med Microbiol. 1999;23(4):289-293. 47.Park SC, Yoon JH, Lee JH, et al. Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett. 2008;271(2):314-322. 48.Deville JL, Bartoli C, Berenguer C, et al. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer. 2009;125(10):2307-2315. 49.Ieta K, Tanaka F, Yokobori T, et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 2009;125(4):926-931. 50.Ramachandran V, Arumugam T, Langley R, et al. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009;4(10):e7502. 51.Nishikawa J, Kitaura M, Matsumoto M, Imagawa M, Nishihara T. Difference and similarity of DNA sequence recognized by VDR homodimer and VDR/RXR heterodimer. Nucleic Acids Res. 1994;22(15):2902-2907. 52.Khorasanizadeh S, Rastinejad F. Nuclear-receptor interactions on DNA-response elements. Trends Biochem Sci. 2001;26(6):384-390. 53.Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78(4):1193-1231. 54.Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001;15(14):2579-2585. 55.Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev. 2002;23(6):763-786. 56.Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene. 2001;20(23):2937-2945. 57.Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2011;108(42):17468-17473. 58.GEO dataset : GSE 12417-GPL96 59.GEO dataset : GSE 12417-GPL570 60.GEO dataset : GSE 5122 61.GEO dataset : GSE 8970 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66448 | - |
| dc.description.abstract | 根據文獻，低氧 (hypoxia) 狀態會促進固態腫瘤細胞進行侵犯 (invasion) 或轉移 (metastasis) 到正常的組織；骨髓內的環境即呈現低氧狀態，但於白血病 (leukemia) 的研究並不多，而急性骨髓性白血病 (AML) 是在一般成人中最常被診斷的白血病，因此我們想探討缺氧狀態在 AML 中所扮演的角色。首先我們利用微陣列分析培養於氧氣濃度 21 % (正常氧) 與 1 % (低氧) 環境下 8 小時的白血病細胞株 (OCI/AML3)，發現在低氧狀態下，腎上腺髓質素 (adrenomedullin，AM) mRNA 表現量約為正常氧的 9 倍。同時，我們利用 Oncomine 網路資料庫發現在 AML 病人與正常人中有不同程度的 AM mRNA 表現，但正常人與 AML 病人之間或不同 AML 亞型之間無明顯差異；我們也分析不同白血病細胞株 (U937、K562、HL-60、OCI/AML3) 及隨機取樣的 AML 病人檢體其 AM mRNA 表現量在不同氧分壓下的變化。結果顯示在低氧環境下，AM mRNA 於各血癌細胞株及 AML 病人檢體的初代培養 (primary culture) 中，表現量有增加的趨勢 (增加倍率有2 - 150倍的差異)。為了實際反應出骨髓內 AM 的角色，我們進一步利用免疫組織化學法分析 AML 病人及骨髓正常之病患的骨髓切片，結果顯示， 在 22 位 AML 病患中，有三位病患具 AM 蛋白的表現，而在 11 例骨髓正常之病患中則有 4 位。已有文獻指出在固態腫瘤中，AM 能透過活化 PI3K/Akt 路徑或 Ras/Raf 路徑，促使腫瘤細胞增生，因此我們欲探討 AM 對白血病細胞的影響。結果顯示，在正常氧環境下，給予 U937 細胞株 AM (1 uM) 48 小時後，會促使 U937 細胞數目增加 20 %；反之，若給予拮抗劑 (1 uM) 48 小時，細胞數目則會降低 20 %；但於其他細胞株無明顯差異。為了釐清 AM 影響 U937 細胞數目的機制，我們分析細胞週期、細胞凋亡比例及觀察促凋亡蛋白 (Bax) 和抗凋亡蛋白 (Bcl-2、Bcl-xL) 表現量之變化。結果顯示，不論是細胞週期、細胞凋亡比例、促凋亡蛋白或抗凋亡蛋白表現量，U937 細胞於加藥前後皆無差異。本研究指出在不同血癌細胞株和部分臨床 AML 病人檢體中可觀察到有 AM mRNA 及蛋白表現，雖然目前結果未能釐清其對血癌細胞的影響與作用，但仍有許多方向可供探討。 | zh_TW |
| dc.description.abstract | Privious studies showed that hypoxia condition can promote cancer cells invasion and metastasis in solid tumors. In fact, the bone marrow microenvironment is in hypoxia condition. However, the involvement of hypoxia in leukemia has not been clearly documented. Because AML is the most common in leukemia, we investigated the roles of hypoxia in AML. First, we analyzed the microarray data of leukemia cell line (OCI/AML3) under normoxia or hypoxia condition. We found that adrenomedullin (AM) mRNA expression under hypoxia is 9-fold higher than normoxia. Meanwhile, we found that AM mRNA were detected in AML patients by Oncomine website database. In addition, we analyzed AM mRNA expression in other leukemia cell lines and clinical AML samples by RT-PCR and real-time RT-PCR. The results also showed that AM mRNA expression under hypoxia increased compared to normoxia. Furthermore, the AM signals were detected in three of twenty- two AML bone marrow samples by immunohistochemstry. However, there were also detected in four of eleven non-AML bone marrow samples. To understand the effects of AM in leukemia, we observed the effects of cell viability in leukemia cell lines. The results revealed in normoxia condition, 1 uM AM treament increased cell numbers of U937 cells. In contrast, when treated with AM antagonist, AMA (1 uM), reduced the cell numbers of U937 cells. To understand the mechanism of AM, which increased cell numbers of U937 cells, we analyzed cell cycle distribution, sub-G1 DNA contents and protein expression of apoptotic-related molecules. However, there were no significant differences in either one of these experiments between drug-treated and untreated cells. The study indicated that there were AM mRNA and protein expression in leukemia cells and clinical AML patient samples. However, the effects and mechanisms of AM in AML are still not clear. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T00:36:20Z (GMT). No. of bitstreams: 1 ntu-101-R98424009-1.pdf: 3102296 bytes, checksum: 86580ae0561e1e82241af9534340d8c1 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 目錄 I
圖目錄 IV 表目錄 V 附圖目錄 VI 附表目錄 VII 縮寫表 VIII 摘要 IX Abstract XI 第一章 前言 1 一. 急性骨髓性白血病 (acute myeloid leukemia, AML) 1 (一) 急性骨髓性白血病之病因 1 (二) 急性骨髓性白血病之分類 1 (三) 急性骨髓性白血病之臨床表現及診斷方法 2 (四) 急性骨髓性白血病之治療 2 (五) 急性骨髓性白血病之預後因子 3 二. 固態腫瘤 (solid tumor) 與缺氧 (hypoxia) 4 三. 腎上腺髓質素 (adrenomedullin，AM) 5 (一) 腎上腺髓質素之生理作用 6 (二) 腎上腺髓質素在細胞內調控之機制 6 第二章 研究目的 8 第三章 材料與方法 9 一. 材料： 9 (一) 細胞 9 (二) 研究對象之選取 9 (三) 儀器設備 10 (四) 藥品 11 (五) 抗體 13 (六) 引子 (primer) 與引子/探針 (primer/probe) 合成 14 (七) 試劑組 14 (八) 其他 14 (九) 藥品與試劑配置 14 二. 方法： 17 (一) 細胞培養 17 (二) RNA 萃取 18 (三) 反轉錄聚合酶連鎖反應 (RT-PCR) 19 (四) 即時監控聚合酶連鎖反應 (Real-time PCR) 19 (五) 細胞生長抑制實驗 (MTS assay) 20 (六) 西方墨點法 (Western Blot) 20 (七) 免疫組織化學法 (Immunohistochemistry) 22 (八) pCMV-Taq 2B-AM 與 pEGFP-N2 質體的建構 22 (九) 製備大腸桿菌勝任細胞 22 (十) 轉型作用 (transformation) 23 (十一) 微量製備質體 DNA 23 (十二) 大量製備質體 DNA 24 (十三) 短暫細胞轉染 (transient transfection) 24 (十四) 細胞週期分析 24 (十五) 細胞凋亡分析 25 (十六) 微陣列 (Microarray) 分析 25 (十七) Ingenuity pathways analysis (IPA) 軟體分析 26 (十八) Oncomine 及 PrognoScan 網路資料庫分析 26 (十九) 統計 27 第四章 結果 28 一. 利用微陣列 (Microarray) 技術篩選出腎上腺髓質素 (AM) 28 二. Oncomine 及 PrognoScan 網路資料庫分析 28 三. AML 與 Non - AML 病患之腎上腺髓質素蛋白表現情形 29 四. 腎上腺髓質素對白血病細胞株增生之影響 30 第五章 討論 31 第六章 參考文獻 34 | |
| dc.language.iso | zh-TW | |
| dc.subject | 腎上腺髓質素 | zh_TW |
| dc.subject | 低氧 | zh_TW |
| dc.subject | 急性骨髓性白血病 | zh_TW |
| dc.subject | hypoxia | en |
| dc.subject | adrenomedullin (AM) | en |
| dc.subject | acute myeloid leukemia (AML) | en |
| dc.title | 缺氧相關分子腎上腺髓質素在急性骨髓性白血病中角色之研究 | zh_TW |
| dc.title | Study on the Roles of Hypoxia-related Adrenomedullin (AM) in Acute Myeloid Leukemia (AML) | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 胡忠怡,郭遠燁,歐大諒,顧雅真 | |
| dc.subject.keyword | 腎上腺髓質素,低氧,急性骨髓性白血病, | zh_TW |
| dc.subject.keyword | adrenomedullin (AM),hypoxia,acute myeloid leukemia (AML), | en |
| dc.relation.page | 88 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-02-02 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 未授權公開取用 | 3.03 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。